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Introduction
Opportunistic fungal infections can cause significant morbidity and mortality in 
immunocompromised patients. The diagnosis and treatment of these infections may be 
challenging.1,2 The manifestation of invasive fungal infection (IFI) is determined by numerous 
factors including the virulence of the fungal species, the adequacy of host immune responses, the 
size of the inoculum inhaled or disruption of mucosal barriers. Individuals at risk for IFIs include 
those who have received transplants, immunosuppressive therapy or chemotherapy for neoplastic 
diseases; HIV-infected patients; premature infants; and individuals with defects in neutrophil, 
monocyte, T-lymphocyte or B-lymphocyte function.3 In the present report, we describe an unusual 
disseminated fungal infection caused by a novel Emmonsia species in an HIV-infected child.
Case report
A 3-year-old boy was admitted to Red Cross War Memorial Children’s Hospital, Cape Town, 
South Africa, with acute gastroenteritis, pneumonia and herpes gingivostomatitis. Six months 
earlier, HIV infection was diagnosed at a primary health care clinic. Antiretroviral therapy (ART) 
was not initiated despite it being indicated for such patients by the South African ART guidelines. 
He was stunted (height 85 cm, height–age z-score – 3) but not wasted (weight 12.6 kg, weight-
for-height z-score +1 [2006 WHO Child Growth Standards]). Blood results on admission showed 
a normocytic anaemia (haemoglobin 6.8 g/dL, reference range 10.7–13.1) and leucopaenia 
(white cell count [WCC] 2.71 × 109/L, reference range 6–18). The differential WCC showed that 
neutropaenia (1.22 × 109/L, reference range 2–5.5) and lymphopaenia (1.49 × 109/L, reference 
range 3.6–12) were present. A chest radiograph showed features of a bilateral pneumonia 
(Figure 1), for which he was commenced on ampicillin and gentamicin, and acyclovir, for the 
pneumonia and herpes gingivostomatitis, respectively. No supplemental oxygen therapy was 
required at admission and empiric treatment for Pneumocystis jirovecii pneumonia was not 
initiated. However, cotrimoxazole prophylaxis was commenced on admission.
He experienced high fevers, peaking at 40 °C. On day 6 of admission, he developed diffuse 
abdominal tenderness and a generalised erythematous maculopapular exanthem. Liver function 
tests (LFTs) showed normal total bilirubin (2 μmol/L, ref. range 0–21) and alkaline phosphatase 
(ALP 268 U/L, ref. range 104–345) concentrations, and elevated γ-glutamyl transferase (GGT 
120 U/L, ref. range 3–22), alanine transaminase (ALT 223 U/L, ref. range 5–30) and aspartate 
transaminase (AST 1304 U/L, ref. range 0–56) concentrations. The C-reactive protein (CRP) 
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Opportunistic fungal infections can cause significant morbidity and mortality in 
immunocompromised patients. We describe a paediatric case of an unusual disseminated 
fungal infection. A three-year-old HIV-infected child with severe immunosuppression (CD4+ 
T-cell count 12 × 106/L) was admitted to hospital with pneumonia, gastroenteritis and herpes 
gingivostomatitis. Despite antibacterial and antiviral therapy, he experienced high fevers 
and developed an erythematous maculopapular rash and abdominal tenderness. The child’s 
condition progressively worsened during the admission. A thermally dimorphic fungus was 
cultured from bone marrow and identified as an Emmonsia species on DNA sequencing. The 
patient made a good recovery on amphotericin B deoxycholate and antiretroviral therapy. 
Itraconazole was continued for a minimum of 12 months, allowing for immune reconstitution 
to occur. This case is the first documented description of disseminated disease caused by a 
novel Emmonsia species in an HIV-infected child in South Africa.
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was changed to ertapenem and fluconazole for presumed 
hospital-acquired infection. There was no growth on blood 
culture after 5 days of incubation, and a urine culture yielded 
mixed bacterial growth. Tuberculin skin testing (Mantoux 
method) and Xpert MTB/RIF (Cepheid, Inc., Sunnyvale, CA, 
USA) on induced sputum specimens were negative. Two 
days later, he had generalised tonic clonic seizures for which 
he received an intravenous loading dose of phenobarbitone. 
The antibiotic was empirically changed to meropenem for 
possible hospital-acquired meningitis. A cerebrospinal 
fluid specimen was bloodstained but there was no bacterial 
growth, and polymerase chain reaction (PCR) assays for 
entero- and herpesviruses were negative.
The fever and maculopapular rash persisted. Repeat CRP 
(88.4 mg/L), procalcitonin (5.3 μg/L, reference range 
0.0–0.5), ferritin (91 705 μg/L, reference range 20–200) 
and triglyceride concentrations (4.7 mmol/L, reference 
range 0.3–1.1) were elevated. The differential diagnosis 
included haemophagocytic lymphohistiocytosis (HLH), 
disseminated tuberculosis and invasive fungal infection. 
The patient subsequently developed respiratory distress 
requiring supplemental nasal prong oxygen therapy. 
Repeat chest radiography was unchanged from admission 
with features not suggestive of tuberculosis or fungal 
infection. He was given packed red blood cell, platelet 
and cryoprecipitate transfusions for severe anaemia 
(Hb 5.6 g/dL), thrombocytopaenia (platelet count 52 × 109/L) 
and hypofibrinogenaemia (fibrinogen concentration 1.0 g/L, 
reference range 1.7 g/L – 4.0 g/L), respectively.
Skin and bone marrow biopsies were performed on day 10 
in hospital. Skin histology showed extensive karyorrhexis 
and numerous dermal histiocytes containing cytoplasmic 
small fungal organisms. Grocott and Periodic acid–Schiff 
stains were positive and suggestive of dermal histoplasmosis 
(Figure 2). Skin culture did not grow fungi or myco-
bacteria. Bone marrow histology revealed histiocytosis and 
haemophagocytosis consistent with a diagnosis of HLH. 
Fungal stains showed scanty structures 1.5 μm × 2.5 μm in 
diameter and morphologically compatible with Histoplasma 
capsulatum. A diagnosis of disseminated fungal infection with 
secondary HLH was made and intravenous amphotericin B 
deoxycholate 1 mg/kg/day commenced 14 days later.
Culture of the bone marrow aspirate in a BACTEC MycoF/
lytic bottle (Becton Dickinson, New Jersey) flagged positive 
after 17.6 days of incubation, and small yeasts were seen on 
Gram stain. The isolate was submitted to the National Institute 
for Communicable Diseases for further identification. The 
fungus was converted from the mycelial to yeast phase on 
brain heart infusion agar with 5% sheep blood (Diagnostic 
Media Products, Sandringham) at 35 °C and morphologically 
characterised based on DNA sequencing of the internal 
transcribed spacer region of the isolate’s ribosomal gene. 
The isolate was identified as the thermally dimorphic fungus 
Emmonsia species. The DNA sequence was the same as 
those of previously described isolates of a novel Emmonsia 
species. An investigational urine Histoplasma antigen test 
(ImmunoMycologics, Norman, OK) was negative.
Source: Radiology Department, Red Cross War Memorial Children’s Hospital
FIGURE 1: Chest radiograph on admission, with features of bilateral pneumonia.
a
b
Source: Dr Komala Pillay, Division of Anatomical Pathology, Red Cross War Memorial 
Children’s Hospital
Note: The arrows identify the organism.
FIGURE 2: Skin histology biopsy demonstrating fungal elements measuring 
1.5 μm × 2.5 μm using (a) Periodic acid-Schiff and (b) Grocott methenamine 
silver stains.
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ART, comprising abacavir, lamivudine and efavirenz, was 
commenced 3 days before amphotericin B was started. 
The LFT concentrations had marginally improved at this 
stage with an ALT of 156 U/L, AST 560 U/L and GGT 
102 U/L. The baseline CD4+ T-cell count (percentage) was 
12 × 106/L (0.45%) and HIV-1 viral load 2 149 305 RNA 
copies/mL. After ART and amphotericin B were 
commenced, he made a remarkable recovery. Within 3 days, 
supplemental oxygen was discontinued and, after 5 days, 
the skin lesions and fever had resolved. The abdominal 
tenderness and abnormal LFTs resolved on day 11 and 12 of 
amphotericin B, respectively.
Daily amphotericin B was continued for 6 weeks via a 
central venous catheter. Adverse effects were minimised 
through pre-emptive hydration before amphotericin B 
infusions, close monitoring of renal function, potassium 
and magnesium concentrations and, where necessary, 
electrolyte replacement. Itraconazole 100 mg daily orally was 
commenced once amphotericin B had been discontinued. 
Because of its potential for reducing the bioavailability 
of itraconazole, efavirenz was replaced with a lopinavir/
ritonavir co-formulation. Six months after commencing ART, 
the patient was well, virologically suppressed (HIV-1 viral 
load < 40 RNA copies/mL), had a CD4+ T-cell (percentage) of 
884 × 106 cells/L (17.9%) and normal LFTs. At last evaluation, 
there was no clinical evidence of active fungal infection. The 
intention is to maintain him on itraconazole for a minimum 
of 12 months and until his CD4 count reaches 25%, before 
considering discontinuation of antifungal therapy.
Discussion
Emmonsia species, a group of dimorphic fungi, are found 
in soil, and some species can cause pulmonary infection in 
rodents.4 The genus currently contains three species, namely 
Emmonsia crescens, Emmonsia parva and Emmonsia pasteuriana. 
Infection caused by Emmonsia species has been described 
in HIV-uninfected adults and one child. The infections were 
caused by E. crescens and E. parva, resulting in predominantly 
pulmonary adiaspiromycosis and occasional cutaneous 
manifestations.4,5,6,7 More recently, invasive infection caused 
by a new species of Emmonsia closely related to E. pasteuriana 
was documented in 13 HIV-infected adults with advanced 
HIV disease in South Africa.8 Our case is the first description 
of disseminated disease caused by this new Emmonsia 
species in an HIV-infected child.
All 13 adult patients presented with very low CD4+ T-cell 
counts, anaemia and widespread skin lesions. The skin 
manifestations ranged from erythematous papules to 
plaques and ulcers. Twelve had a documented fever and 
8 of 9 who underwent LFTs had deranged liver enzymes, 
suggesting hepatic involvement. Our patient similarly 
developed severe immune suppression, anaemia, an 
erythematous papular eruption and deranged LFTs, and 
in addition had neutropaenia and lymphopaenia. In that 
series, the original histological diagnosis on skin biopsy 
samples morphologically resembled H. capsulatum. On gene 
sequencing, the fungus was identified as belonging to the 
genus Emmonsia.8 Not all fungi require molecular diagnosis. 
However, Emmonsia species is difficult to diagnose by 
morphological appearance alone, necessitating molecular 
confirmation. The role of the Beta D Glucan assay in the 
diagnosis of emmonsiosis is currently not known. The assay 
is likely to be elevated but, as it detects most common fungi, 
is unlikely to be specific for Emmonsia species.
Our patient was empirically commenced on fluconazole 
during the course of his clinical deterioration. Fluconazole 
is less active than itraconazole against dimorphic fungi 
especially histoplasmosis, probably explaining the lack of 
clinical response until amphotericin B deoxycholate was 
commenced.9,10 Currently there are no treatment guidelines 
for HIV-associated disseminated Emmonsia infection. 
Our regimen of amphotericin B deoxycholate followed by 
maintenance itraconazole therapy was extrapolated from 
treatment guidelines for other dimorphic fungal infections.11 
Duration of therapy depends on the extent of the disease. As 
our patient had disseminated fungal infection with severe 
immunosuppression, we elected to follow recommendations 
for treating disseminated histoplasmosis in HIV-infected 
patients. Lifelong antifungal prophylaxis may not be 
required in our patient because he has already had a good 
immunological response.12
Itraconazole is metabolised by the cytochrome P450 C3A4 
enzyme. This pathway is also responsible for the metabolism 
of the non-nucleoside reverse transcriptase (NNRTI) 
class of antiretroviral drugs. Theoretically, levels of either 
the itraconazole or NNRTI could be affected. There is a 
paucity of literature describing the drug–drug interactions 
between itraconazole and the NNRTIs. A case report of an 
HIV-infected male patient with disseminated Histoplasma 
infection demonstrated reduced levels of itraconazole and 
an increase in the urine Histoplasma antigen level while 
he was receiving efavirenz. After switching to a protease 
inhibitor, the serum drug levels of itraconazole increased and 
the urine Histoplasma antigen levels declined.13 Drug levels 
of itraconazole were not monitored in the case described 
because the test is not available in South Africa.
Conclusion
The recently published case series and the present case report 
confirm that emmonsiosis occurs among both HIV-infected 
adults and children in South Africa.8 Prolonged incubation 
(up to 6 weeks) of the fungal culture may be necessary 
for the diagnosis. This infection should be considered in 
immunocompromised patients presenting with persistent 
fever and other clinical features suggestive of IFI.
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